Hisamitsu Pharmaceutical Co Stock Cash Per Share
| HTSUFDelisted Stock | USD 30.31 0.00 0.00% |
Hisamitsu Pharmaceutical Co fundamentals help investors to digest information that contributes to Hisamitsu Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Hisamitsu Pink Sheet. The fundamental analysis module provides a way to measure Hisamitsu Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hisamitsu Pharmaceutical pink sheet.
Hisamitsu |
Hisamitsu Pharmaceutical Co Company Cash Per Share Analysis
Hisamitsu Pharmaceutical's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Hisamitsu Pharmaceutical Co has a Cash Per Share of 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The cash per share for all United States stocks is 100.0% higher than that of the company.
Hisamitsu Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hisamitsu Pharmaceutical's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hisamitsu Pharmaceutical could also be used in its relative valuation, which is a method of valuing Hisamitsu Pharmaceutical by comparing valuation metrics of similar companies.Hisamitsu Pharmaceutical is currently under evaluation in cash per share category among its peers.
Hisamitsu Fundamentals
| Return On Equity | 0.0504 | |||
| Return On Asset | 0.0212 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 1.15 B | |||
| Shares Outstanding | 79.53 M | |||
| Shares Owned By Insiders | 26.45 % | |||
| Shares Owned By Institutions | 35.26 % | |||
| Price To Earning | 22.53 X | |||
| Price To Book | 0.97 X | |||
| Price To Sales | 0.02 X | |||
| Revenue | 120.19 B | |||
| Gross Profit | 70.07 B | |||
| EBITDA | 17.3 B | |||
| Net Income | 9.66 B | |||
| Cash And Equivalents | 151.32 B | |||
| Total Debt | 219 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 4.46 X | |||
| Book Value Per Share | 3,393 X | |||
| Cash Flow From Operations | 19.2 B | |||
| Earnings Per Share | 1.06 X | |||
| Number Of Employees | 2.78 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 2.45 B | |||
| Total Asset | 302.86 B | |||
| Retained Earnings | 216.56 B | |||
| Working Capital | 133.88 B | |||
| Current Asset | 171.81 B | |||
| Current Liabilities | 37.93 B | |||
| Z Score | 6.6 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 302.86 B | |||
| Last Dividend Paid | 42.0 |
About Hisamitsu Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hisamitsu Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hisamitsu Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hisamitsu Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Hisamitsu Pink Sheet
If you are still planning to invest in Hisamitsu Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hisamitsu Pharmaceutical's history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |